Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study

BMC Cancer

Table 2 Patient characteristics

	Pmab group N = 32	Cmab group N = 43	P-value
Sex
Male	23 (72%)	30 (70%)	1.00
Age (years)	65.7 (9.0)	63.1 (12.4)	0.33
Body weight (kg)	58.1 (10.0)	57.9 (9.0)	0.91
Body surface area (kg/m²)	1.62 (0.17)	1.60 (0.16)	0.59
Performance Status (ECOG)
0 / 1 / 2	15 (47%) / 16 (50%) / 1 (3%)	27 (63%) / 15 (35%) / 1 (2%)	0.39
Diabetes mellitus	8 (25%)	6 (14%)	0.25
Smoking status
Never / former / current	8 (25%) / 15 (47%) / 9 (28%)	17 (40%) / 16 (37%) / 10 (23%)	0.42
Serum albumin level (g/dl)	3.64 (0.66)	3.74 (0.36)	0.43
Primary origin of tumors
Rectal / colon / other	9 (28%) / 22 (69%) / 1 (3%)	22 (51%) / 18 (42%) / 3 (7%)	0.07
On the left side of the colon / on the right side of the colon^a	21 (66%) / 11 (34%)	33 (78%) / 10 (23%)	0.31
Line of treatment
1st / 2nd / 3rd	25 (78%) / 6 (19%) / 1 (3%)	38 (88%) / 4 (9%) / 1 (2%)	0.47
Combined regimen
FOLFOX / FOLFIRI / LV5FU	22 (69%) / 9 (28%) / 1 (3%)	38 (88%) / 4 (9%) / 1 (2%)	0.10
Concomitant bolus 5-FU
Presence / absence	32 (100%) / 0 (0%)	41 (95%) / 2 (5%)	0.50
Relative dose intensity in cycle 1 (%)	97.3 (7.8)	93.0 (21.6)	0.28
Cetuximab interval^b
Weekly / biweekly	-	13 (30%) / 30 (70%)	-

Data are expressed as mean (SD) and n (%).
^aOn the left side of the colon means descending colon, sigmoid colon, and rectum. On the right side of the colon means the cecum and ascending colon.
^bWeekly means cetuximab administered weekly; the initial dose was 400 mg/m² and the maintenance dose was 250 mg/m². Biweekly means a 500-mg/m² dose of cetuximab administered every other week.